{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Non-small+Cell+Lung+Cancer&page=27",
    "query": {
      "condition": "Squamous Cell Non-small Cell Lung Cancer",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 743,
    "total_pages": 75,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Non-small+Cell+Lung+Cancer&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Squamous+Cell+Non-small+Cell+Lung+Cancer&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T14:50:59.494Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00020709",
      "title": "Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Adenocarcinoma of the Lung",
        "Bronchoalveolar Cell Lung Cancer",
        "Large Cell Lung Cancer",
        "Squamous Cell Lung Cancer",
        "Stage IIIA Non-small Cell Lung Cancer",
        "Stage IIIB Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "gefitinib",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 840,
      "start_date": "2001-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-27",
      "last_synced_at": "2026-10-15T14:50:59.494Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00020709"
    },
    {
      "nct_id": "NCT00006484",
      "title": "Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "tirapazamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-11",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-10-15T14:50:59.494Z",
      "location_count": 93,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006484"
    },
    {
      "nct_id": "NCT00970684",
      "title": "Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Nathan Pennell, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 13,
      "start_date": "2009-09",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2022-08-16",
      "last_synced_at": "2026-10-15T14:50:59.494Z",
      "location_count": 4,
      "location_summary": "Cleveland, Ohio • Mayfield Heights, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Mayfield Heights",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00970684"
    },
    {
      "nct_id": "NCT04504916",
      "title": "A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple-negative Breast Cancer",
        "Non-squamous Non-small-cell Lung Cancer",
        "NSCLC",
        "Estrogen-receptor-positive Breast Cancer",
        "Progesterone-receptor-positive Breast Cancer",
        "Estrogen-receptor-negative Breast Cancer",
        "ER-negative Breast Cancer",
        "Progesterone-receptor Negative Breast Cancer",
        "PR-negative Breast Cancer",
        "HER2-negative Breast Cancer",
        "ER-positive Breast Cancer",
        "PR-positive Breast Cancer",
        "Platinum-resistant Ovarian Cancer",
        "Gastric Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Zilovertamab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2020-10-07",
      "completion_date": "2023-06-12",
      "has_results": true,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-10-15T14:50:59.494Z",
      "location_count": 8,
      "location_summary": "Hollywood, Florida • Orlando, Florida • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04504916"
    },
    {
      "nct_id": "NCT04774952",
      "title": "Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "RMC-5552",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2021-04-07",
      "completion_date": "2024-06-28",
      "has_results": false,
      "last_update_posted_date": "2025-04-15",
      "last_synced_at": "2026-10-15T14:50:59.494Z",
      "location_count": 8,
      "location_summary": "Irvine, California • Sacramento, California • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04774952"
    },
    {
      "nct_id": "NCT03485209",
      "title": "Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Exocrine Pancreatic Cancer",
        "Carcinoma, Squamous Cell of Head and Neck"
      ],
      "interventions": [
        {
          "name": "tisotumab vedotin",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen, a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2018-06-25",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-15T14:50:59.494Z",
      "location_count": 124,
      "location_summary": "Encinitas, California • La Jolla, California • Sacramento, California + 57 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03485209"
    },
    {
      "nct_id": "NCT03652077",
      "title": "A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cervical Cancer",
        "Gastric Cancer",
        "Stomach Cancer",
        "Gastroesophageal Junction Cancer",
        "Esophageal Cancer",
        "Hepatocellular Carcinoma",
        "Melanoma",
        "Uveal Melanoma",
        "Merkel Cell Carcinoma",
        "Mesothelioma",
        "MSI",
        "Non-small Cell Lung Cancer",
        "NSCLC",
        "Ovarian Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "RCC",
        "Triple-negative Breast Cancer",
        "Urothelial Carcinoma",
        "Mismatch Repair Deficiency"
      ],
      "interventions": [
        {
          "name": "INCAGN02390",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-09-24",
      "completion_date": "2021-08-18",
      "has_results": false,
      "last_update_posted_date": "2021-11-15",
      "last_synced_at": "2026-10-15T14:50:59.494Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Jackson, Mississippi • Hackensack, New Jersey + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Huntsville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03652077"
    },
    {
      "nct_id": "NCT02192541",
      "title": "Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Ziv-Aflibercept",
          "type": "DRUG"
        },
        {
          "name": "Ganetespib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 5,
      "start_date": "2014-12-02",
      "completion_date": "2016-02-25",
      "has_results": true,
      "last_update_posted_date": "2018-03-29",
      "last_synced_at": "2026-10-15T14:50:59.494Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02192541"
    },
    {
      "nct_id": "NCT07718737",
      "title": "Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "NSCLC (Advanced Non-small Cell Lung Cancer)"
      ],
      "interventions": [
        {
          "name": "AMT-116",
          "type": "DRUG"
        },
        {
          "name": "Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Multitude Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 512,
      "start_date": "2026-08-28",
      "completion_date": "2028-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-15T14:50:59.494Z",
      "location_count": 2,
      "location_summary": "Port Saint Lucie, Florida • Kingwood, Texas",
      "locations": [
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "Kingwood",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07718737"
    },
    {
      "nct_id": "NCT03228667",
      "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Urothelial Carcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Merkel Cell Carcinoma",
        "Melanoma",
        "Renal Cell Carcinoma",
        "Gastric Cancer",
        "Cervical Cancer",
        "Hepatocellular Carcinoma",
        "Microsatellite Instability",
        "Mismatch Repair Deficiency",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "N-803 + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Avelumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Pembrolizumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Nivolumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Atezolizumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Avelumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Durvalumab + PD-L1 t-haNK",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Docetaxel + Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "N-803 + Docetaxel + Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-12-11",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-14",
      "last_synced_at": "2026-10-15T14:50:59.494Z",
      "location_count": 35,
      "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03228667"
    }
  ]
}